NGHIÊN CỨU ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG BỆNH GAN NHIỄM MỠ KHÔNG DO RƯỢU Ở BỆNH NHÂN ĐÁI THÁO ĐƯỜNG TÍP 2 TẠI BỆNH VIỆN QUÂN Y 175

Tiến Đào Đức; Khánh Hoàng Ngọc; Hiều Trần Văn

doi:10.59354/ydth175.2025.399

Authors

Tiến Đào Đức Bệnh viện Quân y 175
Khánh Hoàng Ngọc Phân hiệu phía Nam, Học viện Quân y
Hiều Trần Văn Bệnh viện Quân y 175

DOI:

https://doi.org/10.59354/ydth175.2025.399

Keywords:

Non-alcoholic fatty liver disease, Fibroscan, type 2 diabetes

Abstract

Objectives: To determine the prevalence and describe the clinical, subclinical characteristics of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus at Military Hospital 175.

Materials and methods: A prospective, cross-sectional study was conducted on 152 patients with type 2 diabetes mellitus attending Military Hospital 175 between November 2023 and November 2024. NAFLD was diagnosed based on a Controlled Attenuation Parameter (CAP) score of ≥ 234 dB/m, measured by FibroScan. Clinical and paraclinical data were collected and compared between the NAFLD and non[1]NAFLD groups.

Results: The prevalence of NAFLD was 67.11%. The NAFLD cohort was predominantly male, with a mean age of 59.24 ± 10.28 years. Common comorbidities included overweight or obesity (75.49%), dyslipidemia (70.91%), and hypertension (68.06%). Notably, 58.82% of patients with NAFLD were asymptomatic. Compared to the non-NAFLD group, patients with NAFLD had significantly higher levels of glucose, HbA1c, GGT, triglycerides, total cholesterol, and greater liver stiffness values (p < 0.05). Severe steatosis (S3) was the most common grade (54.90%), and significant liver fibrosis (≥ F2) was present in 41.18% of patients.

Conclusion: NAFLD is a highly prevalent comorbidity in patients with type 2 diabetes mellitus and is often asymptomatic despite the presence of significant liver damage. Therefore, routine screening with non-invasive methods is essential for early detection and timely intervention.

References

1. Powell E. E., Wong V. W., Rinella M. (2021). Non-alcoholic fatty liver disease. Lancet, 397(10290): 2212-2224.

2. Ballestri S., Zona S., Targher G., et al. (2016). Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta‐analysis. Journal of gastroenterology and hepatology, 31(5): 936-944.

3. Association A. D. (2022). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care, 45(Suppl 1): S17-s38.

4. Karlas T., Petroff D., Garnov N., et al. (2014). Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One, 9(3): e91987.

5. Tuong T. T. K., Tran D. K., Phu P. Q. T., et al. (2020). Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using FibroScan. Diagnostics, 10(3): 159.

6. Younossi Z. M., Golabi P., de Avila L., et al. (2019). The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta analysis. J Hepatol, 71(4): 793-801.

7. En Li Cho E., Ang C. Z., Quek J., et al. (2023). Global prevalence of non alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut, 72(11): 2138-2148.

8. Kwon Y.-M., Oh S.-W., Hwang S.-s., et al. (2012). Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Official journal of the American College of Gastroenterology| ACG, 107(12): 1852-1858. 9. Zhao Y. C., Zhao G. J., Chen Z., et al. (2020). Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension, 75(2): 275-284.

10. Deprince A., Haas J. T., Staels B. (2020). Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab, 42: 101092.

11. Ahmed M. (2015). Non-alcoholic fatty liver disease in 2015. World journal of hepatology, 7(11): 1450-1459.

12. Novakovic T., Mekic M., Smilic L., et al. (2014). Anthropometric and biochemical characteristics of patients with nonalcoholic fatty liver diagnosed by non invasive diagnostic methods. Med Arch, 68(1): 22-26.

13. Cernea S. (2024). NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay. Life (Basel), 14(2).